Metis TechBio revenue and financials
In the fiscal year ended December 2025, Metis TechBio reported revenue of ¥105M (+6,985.02% year over year). The net loss was ¥391.84M.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +6,985.02%
- 2025 vs 2024
- Net margin
- -373.2%
- 2024: -33,684.1%
How Metis TechBio is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 474.4% a year on average over the last 3 years
Compound annual growth rate: from ¥554K in 2022 to ¥105M in 2025.
Operating margin rose from −68,012.5% to −356.6%
Operating income over revenue, 2022 → 2025: 67,655.8 percentage points.
Shares outstanding down 20.9% in 3 years
Average diluted shares, 2022 → 2025: with fewer shares, each one represents a larger stake in the company.
Profitable in 0 of 4 fiscal years
Positive net income, fiscal years 2022–2025.
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 105 | 1.5 | 9.3 | 0.6 |
| Cost of revenue | 1.9 | 0.7 | 3.8 | 0.2 |
| Gross profit | 103 | 0.8 | 5.6 | 0.3 |
| Selling, general and administrative | 224 | 111 | 112 | 136 |
| Research and development | 270 | 274 | 290 | 249 |
| Operating income | -374 | -371 | -393 | -377 |
| EBIT | -374 | -371 | -393 | -377 |
| EBITDA | -345 | -338 | -364 | -371 |
| Interest expense | 31.8 | 168 | 70.2 | 1.9 |
| Pre-tax income | -392 | -499 | -582 | -513 |
| Income tax | 0.1 | 0.0 | 0.0 | 0.0 |
| Net income | -392 | -499 | -582 | -513 |
| Net income to common shareholders | -392 | -499 | -582 | -513 |
| Basic EPS | -0.47 | -0.64 | -0.72 | -0.48 |
| Diluted EPS | -0.47 | -0.64 | -0.72 | -0.48 |
| Average shares (basic) | 841 | 784 | 806 | 1,064 |
| Average shares (diluted) | 841 | 784 | 806 | 1,064 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Total revenue | 77.1 | 77.1 | 3.4 | 0.6 | 0.6 | 0.4 |
| Cost of revenue | 0.6 | 0.6 | 1.6 | 0.1 | 0.1 | 0.3 |
| Gross profit | 76.5 | 76.5 | 1.8 | 0.4 | 0.4 | 0.1 |
| Selling, general and administrative | 57.0 | 57.0 | 73.3 | 30.5 | 30.5 | 31.6 |
| Research and development | 86.2 | 86.2 | 85.9 | 58.2 | 58.2 | 70.8 |
| Operating income | -69.1 | -69.1 | -144 | -87.0 | -87.0 | -93.6 |
| EBIT | -69.1 | -69.1 | -144 | -87.0 | -87.0 | -93.6 |
| EBITDA | -62.4 | -62.4 | -138 | -78.3 | -78.3 | -86.2 |
| Interest expense | 1.1 | 1.1 | 1.1 | 14.8 | 14.8 | 43.5 |
| Pre-tax income | -75.0 | -75.0 | -145 | -95.7 | -95.7 | -123 |
| Income tax | 1.6 | 1.6 | 0.1 | — | — | 0.0 |
| Net income | -76.6 | -76.6 | -145 | -95.7 | -95.7 | -123 |
| Net income to common shareholders | -76.6 | -76.6 | -145 | -95.7 | -95.7 | -123 |
| Basic EPS | -0.08 | -0.08 | -0.17 | -0.12 | -0.12 | -0.15 |
| Diluted EPS | -0.08 | -0.08 | -0.17 | -0.12 | -0.12 | -0.15 |
| Average shares (basic) | 910 | 910 | 877 | 813 | 813 | 798 |
| Average shares (diluted) | 910 | 910 | 877 | 813 | 813 | 798 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | 1,290 | 1,049 | 1,313 | 617 |
| Current assets | 1,149 | 819 | 1,026 | 420 |
| Cash and equivalents | 828 | 558 | 561 | 364 |
| Short-term investments | 267 | 21.4 | 280 | 20.0 |
| Receivables | 0.6 | 3.6 | 176 | 5.4 |
| Net property, plant and equipment | 93.7 | 73.0 | 106 | 173 |
| Other intangible assets | 4.3 | 5.1 | 6.4 | 1.5 |
| Long-term investments | — | 108 | 125 | 10.0 |
| Current liabilities | 172 | 109 | 98.2 | 609 |
| Accounts payable | 10.6 | 10.7 | 9.4 | 9.6 |
| Total debt | 131 | 93.0 | 129 | 671 |
| Total liabilities | 249 | 2,431 | 2,291 | 707 |
| Total equity (incl. minority) | 1,041 | -1,382 | -978 | -90.1 |
| Retained earnings | -1,750 | -1,682 | -1,183 | -601 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Total assets | 3,314 | 3,314 | 1,290 | — | — | 1,049 |
| Current assets | 3,034 | 3,034 | 1,149 | — | — | 819 |
| Cash and equivalents | 2,527 | 2,527 | 828 | — | — | 558 |
| Short-term investments | 232 | 232 | 267 | — | — | 21.4 |
| Receivables | 137 | 137 | 0.6 | — | — | 3.6 |
| Net property, plant and equipment | 82.8 | 82.8 | 93.7 | — | — | 73.0 |
| Other intangible assets | 3.5 | 3.5 | 4.3 | — | — | 5.1 |
| Long-term investments | 150 | 150 | — | — | — | 108 |
| Current liabilities | 172 | 172 | 172 | — | — | 109 |
| Accounts payable | 17.9 | 17.9 | 10.6 | — | — | 10.7 |
| Long-term debt | 60.0 | 60.0 | — | — | — | — |
| Total debt | 179 | — | 131 | — | — | — |
| Total liabilities | 296 | 296 | 249 | — | — | 2,431 |
| Total equity (incl. minority) | 3,018 | 3,018 | 1,041 | — | -1,382 | -1,382 |
| Retained earnings | -1,903 | -1,903 | -1,750 | — | — | -1,682 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -122 | -239 | -192 | -138 |
| Depreciation and amortization | 37.5 | 39.7 | 39.5 | 6.9 |
| Capital expenditure | -18.7 | -3.3 | -49.5 | -57.4 |
| Investing cash flow | 35.1 | 78.9 | -405 | 1.2 |
| Financing cash flow | 369 | 143 | 800 | 167 |
| Share repurchases | 0.0 | 0.0 | -84.8 | 0.0 |
| Debt issued | 40.0 | 10.0 | 374 | 87.7 |
| Debt repaid | -34.4 | -50.2 | -98.0 | -4.2 |
| Effect of exchange rates | -12.4 | 13.1 | -5.6 | 4.9 |
| Net change in cash | 271 | -3.8 | 197 | 34.3 |
| Free cash flow | -140 | -243 | -242 | -196 |
| Levered free cash flow | -13.2 | -20.4 | -351 | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Operating cash flow | -81.1 | -81.1 | 19.6 | -48.2 | -48.2 | -73.5 |
| Depreciation and amortization | 9.1 | 9.1 | 8.9 | 10.3 | 10.3 | 9.0 |
| Capital expenditure | -2.7 | -2.7 | -6.4 | -1.4 | -1.4 | -0.9 |
| Investing cash flow | -100 | -100 | 14.2 | -26.8 | -26.8 | 105 |
| Financing cash flow | 1,046 | 1,046 | -6.6 | 8.9 | 8.9 | -3.7 |
| Share repurchases | — | — | -0.9 | — | — | — |
| Debt issued | 50.0 | 50.0 | 0.0 | 20.0 | 20.0 | 10.0 |
| Debt repaid | -25.6 | -25.6 | -5.6 | -10.8 | -10.8 | -13.7 |
| Effect of exchange rates | -15.4 | -15.4 | -5.9 | -1.6 | -1.6 | 11.5 |
| Net change in cash | 849 | 849 | 21.4 | -67.7 | -67.7 | 39.0 |
| Free cash flow | -83.8 | -83.8 | 13.2 | -49.5 | -49.5 | -74.4 |
| Levered free cash flow | 8.2 | -128 | — | — | — | — |
Financial statements of similar companies
Companies in the group: same industry, similar size
